Cubit is an integrated immunoassay and molecular benchtop analyzer designed to simplify clinical workflows and expand the reach of high-quality diagnostics. Powered by proprietary extraction technologies and low-cost microfluidic solutions, the Cubit platform is designed to deliver actionable results at the point of care, targeting turnaround times of approximately 20 minutes or less.
Designed to achieve lab-level analytical performance, including robust detection across challenging sample types, with a focus on minimizing invalid results and system interruptions.
Designed to enable a unified workflow across immunoassay and molecular testing, eliminating the need for multiple platforms and complex testing protocols.
Planned to support a broad and expanding menu of assays, including applications in infectious disease, women’s health, respiratory, cardiology, and gastrointestinal testing.
Designed to enable same-visit clinical decision-making with rapid turnaround times.
Designed for ease of use with minimal hands-on time and simplified workflows suitable for decentralized clinical settings.
Designed for cost-efficient manufacturing and scalable economics, supporting sustainable deployment across a range of care settings.
The Cubit platform is designed to support a growing menu of assays across multiple specialties, with each new assay leveraging the same installed base.
From concept to real-world impact.
Development funding received from the Biomedical Advanced Research and Development Authority.
External evaluation conducted using clinical samples to support performance characterization.
First RADx grant received supporting platform feasibility and development.
Supporting assay development & cartridge integration for HCV.
Expanded federal support recognizing the platform's public health impact.
Initial SAFE financing completed.
We are pleased to receive funding from and collaborate with world-renowned organizations and innovators.
Learn more about our mission-driven platform and the science powering the next generation of point-of-care diagnostics.
Sponsored Research
Cubit is proud to work with select Universities to sponsor technology development and research projects. As part of this research, Cubit provides support for indirect costs up to a maximum rate of 20% of the total direct costs of the project. This maximum rate applies uniformly across all sponsored research projects.
Disclaimer
This website contains forward-looking statements regarding product development, performance targets, and future capabilities. Actual results may differ based on regulatory, technical, and clinical outcomes.
